All In Biotech

Drug Trial Radar · NCT00244140

Ultravist: Safety and Efficacy in Computed Tomography of Head and Body

Ultravist 370 Milligrams of Iodine Per Milliliter (mg I/mL): Safety and Efficacy in Computed Tomography of Head and Body

Last checked: Nov 20, 2026Latest source record: Feb 28, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

435

Actual

Start

Oct 2005

Primary completion

Apr 2008

Study completion Apr 2008

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
First posted
Oct 26, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Diagnostic
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a research study involving the use of a contrast agent called Ultravist Injection. Ultravist, the study drug, is used to improve the pictures obtained using computed tomography (CT). Ultravist acts like a dye to make CT pictures brighter and easier to read. In the case of this study, it will be injected into a vein in the patient's arm; from there, it travels through the blood stream and to the areas to be examined. CT scans will then be taken of the patient's head and/or body as ordered by his/her physician. Phase IIIb Study to Document the Safety and Efficacy of Ultravist 370 mg I/ml, When Administered Intravenously, in Volumes up to 162.2 ml, for Clinically Indicated Contrast Enhanced Computed Tomography (CECT) of the Head and/or Body

Conditions

  • Computed Tomography
  • Diagnostic Imaging

Interventions

  • Iopromide 370 mg I/mLDrug

    Iopromide (Ultravist 370 mg I/mL) administered intravenously

  • Iopromide 300 mg I/mLDrug

    Iopromide (Ultravist 300 mg I/mL) administered intravenously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Quality of Visualization of the Contrast-Enhanced Computed Tomography (CECT) Images, Based on the Blinded Readers' Assessment.Time frame: post administration assessment of study images

Locations

23 sites in 4 countries. Site status is shown where the registry gives one.

  • Site not named

    Tucson, Arizona

  • Site not named

    Miami, Florida

  • Site not named

    Tallahassee, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Atlanta, Georgia

  • Site not named

    Evanston, Illinois

  • Site not named

    Baltimore, Maryland

  • Site not named

    Boston, Massachusetts

  • Site not named

    Boston, Massachusetts

  • Site not named

    Boston, Massachusetts

  • Site not named

    Ann Arbor, Michigan

  • Site not named

    Detroit, Michigan

  • Site not named

    New York, New York

  • Site not named

    Stony Brook, New York

  • Site not named

    Cleveland, Ohio

  • Site not named

    Danville, Pennsylvania

  • Site not named

    Charleston, South Carolina

  • Site not named

    Bogotá, Colombia

  • Site not named

    Medellín, Antioquia, Colombia

  • Site not named

    Mumbai-400026, India

  • Site not named

    Tamil Nadu, India

  • Site not named

    Seoul, South Korea

  • Site not named

    Seoul, Seoul Teugbyeolsi, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.